Search clinical trials for: B-Cell Lymphoma

Total 10648 results

Mayo Clinic

Not yet recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (Starlight-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Sinocelltech Ltd.

Not yet recruiting

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, B-cell

China
Guangdong Ruishun Biotech Co., Ltd
Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital

Not yet recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

B-cell Non-Hodgkin's Lymphoma
Peking University Cancer Hospital & Institute

Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

China
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Spain, Italy, Thailand, Turkey, Australia, Taiwan
920th Hospital of Joint Logistics Support Force...
Shanghai PerHum Therapeutics Co., Ltd.

Recruiting

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell | CAR-T

China
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia | B-Cell Lymphoblastic Leukemia

United States
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis (CMV CAR-T)

B Cell Lymphoma | Acute Leukemia | Cytomegalovirus Infections
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Multiple Myeloma | B-Cell Non-Hodgkin Lymphoma

United States
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell Lymphoma

China
Guangdong Second Provincial General Hospital

Recruiting

JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma

Relapsed or Refractory B-cell Lymphoma

China
Antengene Biologics Limited

Recruiting

A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

Advanced Solid Tumors | B-cell Non-Hodgkin Lymphomas

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life (LNH012)

DLBCL - Diffuse Large B Cell Lymphoma

Italy
Vinmec Research Institute of Stem Cell and Gene...
National Institute of Hematology and Blood Transfusion, Vietnam

Recruiting

CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

B-Cell Non Hodgkin Lymphoma | B-Cell Acute Lymphoblastic Leukemia

Vietnam
Ruijin Hospital

Not yet recruiting

Real-World Study of DLBCL With Different Genetic Subtypes

Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma

China
IRCCS San Raffaele

Recruiting

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Italy
Fondazione Italiana Linfomi - ETS
Roche Pharma AG

Not yet recruiting

A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice (FIL_MAB)

Non-Hodgkin Lymphoma, B-cell

Italy
Huazhong University of Science and Technology

Recruiting

Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression

Diffuse Large B Cell Lymphoma

China
Juventas Cell Therapy Ltd.

Not yet recruiting

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma
Uppsala University
Karolinska University Hospital; Uppsala University Hospital; Elicera Therapeutics

Not yet recruiting

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) (CARMA-01)

B-cell Lymphoma

Sweden
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
University of Birmingham
Regeneron Pharmaceuticals; Cancer Research UK; Fight Kids Cancer; ADC Therapeutics...

Not yet recruiting

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL)

B-cell Non Hodgkin Lymphoma
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Memorial Sloan Kettering Cancer Center

Recruiting

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Lymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell Lymphoma

United States
Weill Medical College of Cornell University
Epizyme, Inc.; American Society of Clinical Oncology; Applebaum Foundation

Recruiting

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Lymphoma

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
920th Hospital of Joint Logistics Support Force...

Recruiting

A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies

B-Cell Leukemia | B-Cell Lymphoma | B-cell Tumors

China
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Nanchang University

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Nanchang University

China
Ruijin Hospital

Recruiting

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

CNS Lymphoma

China
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

Refractory Lymphoma | Relapse | B-cell Non Hodgkin Lymphoma

Italy
Ruijin Hospital

Not yet recruiting

Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

China
IDP Discovery Pharma S.L.

Recruiting

A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)

Chronic Lymphocytic Leukemia (CLL) | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Multiple Myeloma (MM) | High Grade B-Cell Lymphoma, Not Otherwise Specified | Double Hit Lymphoma | Triple Hit Lymphoma

Spain

Search clinical trials for: B-Cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations